Intellimedix, a big data molecular profiling company, announced today that renowned Atlanta entrepreneur Chris Klaus, founder and former CTO of Internet Security Systems, has made a significant investment in the company.

"Chris's investment into Intellimedix validates everything we are doing. His success and expertise in the software industry maps well to our computational strength as a big data genomics company," says Jim Jacoby, founder and Chairman of Intellimedix. "Additionally, his deep ties with Georgia Tech bind us even tighter to that institution. Our chief science officer, Jeffrey Skolnick, is the university's director of the Center for the Study of Systems Biology and an Eminent Scholar in Computational Systems Biology."

Intellimedix, whose notable partnerships include Pfizer, Georgia Tech, Beijing Genomics Institute, Epilepsy Foundation, MIT, and Emory University, compresses the time needed to treat diseases by uniting molecular profiling with drug repurposing and discovery.  Klaus possesses a keen interest in the neurosciences and recently led NeuroLaunch, the world's first accelerator program for early-stage startups related to neuroscience. Intellimedix, a participant in the February 3 event in Atlanta, demonstrated to Klaus and other attendees how the company is leveraging advanced algorithms to power precision medicine.

"As a technology pioneer in the field of personalized medicine, Intellimedix is poised to make significant discoveries that change both the pharmaceutical industry and, more importantly, patients' lives," says Klaus. "I am very impressed by what this company is doing and am proud to support its mission. I look forward to being a part of its long-term success."

Intellimedix was founded by Atlanta real estate mogul Jim Jacoby and several other parents who are fathers of children diagnosed with a rare form of pediatric epilepsy. Dedicated to developing treatments for those suffering from a wide range of diseases, Intellimedix first identifies the root cause of the disease, then uses its sophisticated algorithms to mine the thousands of FDA approved drugs on the market to find the precise ones that can be prescribed to successfully treat the disease. Scientists then test the drugs using in vivo (in living) zebrafish models with a given patient's exact mutation to determine which drugs are most effective for the patient. This model can more accurately match a drug treatment to a patient and ultimately address the underlying cause of the disease.